Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LB-DTK-MV is an allogeneic cell therapy product derived from a third-party donor and is supplied as a pale-yellow cell suspension at a final concentration of 4x10\^7cells/2mL in a colorless, transparent freeze-dried vial. The product is stored frozen until thawed into liquid before administration. Study participants will receive a single intravenous infusion of the assigned cell dose (low dose:…”In the company’s words, NCT07670468 on ClinicalTrials.gov
- Tested for
- BKV Infection, EBV Infection, CMV Infection
- Main trialPhase 1/2
- “The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after anticancer therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The main questions it aims to answer are: * What is the maximum tolerated dose of LB-DTK-MV based on dose-limiting toxicity? * Does the number of CMV, BKV, or EBV virus viral load decrease within 7 or 14 days after the second infusion of LB-DTK-MV? * Do treatment emergent adverse events…”In the company’s words, NCT07670468 on ClinicalTrials.gov
Other drugs for EBV Infection
- TisagenlecleucelNovartis · Phase 3
- TabelecleucelPierre Fabre Medicament · Atara Biotherapeutics · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- MK-1045Merck & Co. · Phase 2/3
- YK012Excyte Biopharma Ltd · Phase 1/2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up1
- 4 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 4 Jun 2027 | Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026